Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy.
We describe the case of a diabetic patient who developed a severe invasive fungal infection due to Rhizopus species postoperatively after a dual heart/kidney transplantation with subsequent intensive immunosuppressive therapy. No improvement was noted with amphotericin B (deoxycholate) therapy, but salvage treatment with the new azole antifungal posaconazole (200 mg orally 4 times daily) resulted in dramatic clinical improvement as early as 1 week after the initiation of therapy that continued through 23 weeks of treatment, with marked clinical, mycological, and radiological improvements and no adverse events.
Tobón
Angela Ma
AM
Corporación para Investigaciones Biológicas, Medellín, Colombia.
Arango
Myrtha
M
Fernández
Darío
D
Restrepo
Angela
A
D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D048909:Diabetes Complications; D016027:Heart Transplantation; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009091:Mucormycosis / Q000188:drug therapy*; D011183:Postoperative Complications / Q000517:prevention & control*; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole